Drug Profile
Research programme: Helicobacter infection therapeutics - Arietis Corporation
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Arietis Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Helicobacter-infections in USA
- 01 Oct 2012 Early research in Helicobacter infections in USA (unspecified route)